Merus N.V.
Clinical trials sponsored by Merus N.V., explained in plain language.
A clinical-stage biopharmaceutical company developing bispecific antibody therapies for cancer.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
-
Can a Two-Target antibody shrink Hard-to-Treat cancers?
Disease control Recruiting nowThis trial is testing an experimental drug called petosemtamab (MCLA-158) in people with advanced solid tumors, including colorectal, head and neck, and lung cancers. The drug is a bispecific antibody designed to block two cancer-related proteins, EGFR and LGR5. Researchers want …
Phase 1/2 • Sponsor: Merus B.V. • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
New combo therapy aims to boost survival in head and neck cancer
Disease control Recruiting nowThis study tests whether adding petosemtamab to the standard immunotherapy pembrolizumab helps people with advanced head and neck cancer live longer. About 700 adults with PD-L1 positive cancer that has spread or come back will receive either the combination or pembrolizumab alon…
Phase 3 • Sponsor: Merus B.V. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC